


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) Pharmaceuticals *characterised by* the formula (I)




wherein

V denotes a peptide with a binding sequence $-X^1\text{Gly}-X^2\text{-Val-Tyr-Ile-His-Pro-}X^3$,

L denotes ~~an optional~~ a bond or a linker of formula $-\text{NH}-(\text{CH}_2)_m-$ optionally combined with $-\text{CO}-(\text{CH}_2)_m\text{-CO}-$ where m denotes a positive integer from 1 to 10,

Z denotes a ~~group~~chelating agent of formula (VII)



(VII)

wherein:

each R^1 , R^2 , R^3 and R^4 is independently H or C_{1-10} alkyl, C_{3-10} alkylaryl, C_{2-10} alkoxyalkyl, C_{1-10} hydroxyalkyl, C_{1-10} alkylamine, C_{1-10} fluoroalkyl, or 2 or more R groups, together with the

Appl. No. 10/559,886

Amdt. Dated December 21, 2009

Reply to Office Action of September 28, 2009

atoms to which they are attached form a carbocyclic, heterocyclic, saturated or unsaturated ring, that optionally can carry an imaging moiety M,

n is 0 or 1;

X¹ denotes an amino acid;

X² denotes Arg, N-alkylated Arg, or a mimetic of Arg Phe[4-guanidino] or Gly-4-piperidyl [N-amidino],

X³ denotes an amino acid containing a hydrophobic side-chain,

and wherein the residues Val and Ile at position 3 and 5 respectively may optionally be replaced with amino acids capable of forming a bridge containing a -CH₂-CH₂-, -S-CH₂-, -S-CH₂-S-, lactam or -S-S- unit,


Z forms a bond with the amino acid Gly optionally through the linker L, and

M where present denotes ~~an imageable moiety capable of detection either directly or indirectly in a diagnostic imaging procedure~~ a gamma emitting moiety for Radio or SPECT imaging selected from the group of ⁶⁷Ga, ¹¹¹In, ¹²³I, ¹²⁵I, ¹³¹I, ^{81m}Kr, ⁹⁹Mo, ^{99m}Tc, ²⁰¹Tl and ¹³³Xe.

2. (Withdrawn) Pharmaceuticals of claim 1 useful in the treatment of heart failure, cardiac arrhythmias and other diseases where fibrosis is prominent and in the treatment of COPD, liver fibrosis and atherosclerosis..

3. (Cancelled) Pharmaceuticals of claim 1 for the use in diagnosis wherein M is an in vivo imageable moiety

4. (Cancelled) Pharmaceuticals of claim 1 wherein Z denotes a chelating agent of formula (VII)




(VII)

wherein:

each R^1 , R^2 , R^3 and R^4 is independently H or C_{1-10} alkyl, C_{3-10} alkylaryl, C_{2-10} alkoxyalkyl, C_{1-10} hydroxyalkyl, C_{1-10} alkylamine, C_{1-10} fluoroalkyl, or 2 or more R groups, together with the atoms to which they are attached form a carbocyclic, heterocyclic, saturated or unsaturated ring.

5. (Cancelled) Pharmaceuticals of claim 1 wherein Z denotes a chelating agent of formula (XI)



(XI)

wherein Q_1 - Q_6 are independently Q groups, where Q is H, alkyl, aryl or an amine protecting group.

W_1 is $-NR-$, $-CO_2-$, $-CO-$, $-NR(C=S)-$, $-NR(C=O)-$, $-CONR-$

or a Q group;

each Y is independently a *D*- or *L*- amino acid, $-CH_2-$, $-CH_2OCH_2-$ or $-OCH_2CH_2O-$ or an X group;

p is an integer of value 1 to 8;

Appl. No. 10/559,886

Amdt. Dated December 21, 2009

Reply to Office Action of September 28, 2009

q is an integer of value 0 to 30;

R is H, C₁₋₄ alkyl, C₂₋₄ alkoxyalkyl, C₁₋₄ hydroxyalkyl, or C₁₋₄ fluoroalkyl;


Q is




A is a counterion;

6. (Cancelled) Pharmaceuticals of claim 1 wherein M represents a gamma emitting moiety for Radio or SPECT imaging comprising ⁶⁷Ga, ¹¹¹In, ¹²³I, ¹²⁵I, ¹³¹I, ^{81m}Kr, ⁹⁹Mo, ^{99m}Tc, ²⁰¹Tl and ¹³³Xe.

7. (Currently Amended) Pharmaceuticals of claim 1 ~~for use in therapy~~ having the formulas (X) or (XII)




Formula (X)




Formula (XII)

or use as diagnostic agent having the formulas (Xa) or (XIIa)



Formula (Xa)



Formula (XIIa)

8. (Original) Pharmaceutical formulation comprising a compound of formula (I) of claim 1 together with one or more pharmaceutical acceptable additives and/or excipients.

9. (Withdrawn) Use of pharmaceuticals of claim 1 for the treatment and/or diagnosis of heart failure, cardiac arrhythmias and other diseases where fibrosis is prominent specifically COPD, liver fibrosis and atherosclerosis.

10. (Withdrawn) Method of in vivo diagnosis of heart failure and other diseases where fibrosis is prominent specifically COPD, liver fibrosis and atherosclerosis in a subject comprising administration of the pharmaceuticals of formula (I) in claim 1 followed by generation of an image of part or all of said subject

11. (Withdrawn) A kit for the preparation of a radiopharmaceutical composition of formula (I) comprising a peptide-chelate conjugate and a reducing agent.